Logotype for OrganiGram Holdings Inc

OrganiGram (OGI) Q4 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for OrganiGram Holdings Inc

Q4 2025 earnings summary

17 Dec, 2025

Executive summary

  • Achieved record gross and net revenue, adjusted EBITDA, and international sales in fiscal 2025, maintaining #1 Canadian recreational market share at 11.9% and strong brand performance nationally.

  • Motif Labs and Collective Project acquisitions expanded extraction, beverage, and U.S. market presence, with significant operational synergies realized and no market share dilution.

  • Expanded international business with record sales in Germany, UK, Australia, and the U.S., and formalized an international business unit.

  • Advanced operational scale and innovation with FASTTM technology, genomics R&D, and seed-based cultivation, supporting future growth.

  • Launched new products and prepared for further launches in vapes, pre-rolls, and beverages, focusing on margin improvement and operational optimization.

Financial highlights

  • Fiscal 2025 gross revenue rose 63% year-over-year to $403.0M; net revenue up 62% to $259.2M; Q4 net revenue was $80.1M, up 79% year-over-year.

  • International sales reached $26.3M for fiscal 2025, up 173% year-over-year.

  • Adjusted gross profit for Q4 increased 85% to $30.6M; full-year adjusted gross margin was 35%, with Q4 margin at 38%.

  • Adjusted EBITDA for Q4 was $9.8M, up 68%–72% sequentially; full-year adjusted EBITDA was $21.9M, up 160% year-over-year.

  • Fiscal 2025 net loss decreased 46% to $24.8M, despite a Q4 net loss of $38M due to non-cash mark-to-market adjustments.

  • Cash and short-term investments at year-end totaled $84.4M, with no material debt.

Outlook and guidance

  • Fiscal 2026 net revenue expected to exceed $300M, with further improvements in adjusted gross margin and EBITDA, and positive free cash flow anticipated.

  • Capital expenditures projected below $10M, down from $17M in fiscal 2025.

  • Anticipate continued strong international growth, especially in vapes, pre-rolls, and new product categories, supported by innovation and EU-GMP certification.

  • Gross margin expected to approach 40% in fiscal 2026, driven by operational improvements and Motif synergies.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more